View:
Download DOC
Download PDF
Download XLS
S-1/A

As filed with the Securities and Exchange Commission on December 29, 2022

Registration Statement No. 333-268797

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

AMENDMENT NO. 1

TO

FORM S-1

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

GE HealthCare Technologies Inc.

(Exact name of Registrant as specified in its charter)

 

 

 

Delaware   3844   88-2515116
(State or Other Jurisdiction of
Incorporation or Organization)		   (Primary Standard Industrial
Classification Code Number)		   (I.R.S. Employer
Identification No.)

 

 

500 W. Monroe Street

Chicago, IL

617-443-3400

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

 

Frank R. Jimenez, Esq.

500 W. Monroe Street

Chicago, IL

60661

617-443-3400

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 

 

With copies to:

Christodoulos Kaoutzanis, Esq.

John C. Kennedy, Esq.

Paul, Weiss, Rifkind, Wharton & Garrison LLP

1285 Avenue of the Americas

New York, NY 10019

212-373-3000 (Telephone)

212-757-3990 (Facsimile)

 

 

Approximate date of commencement of proposed sale to the public:

As soon as practicable after the effective date of this Registration Statement.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, as amended (the “Securities Act”), check the following box.    ☒

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.    ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.    ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.    ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer   ☐    Accelerated filer    ☐
Non-accelerated filer   ☒    Smaller reporting company    ☐
     Emerging growth company    ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(b) of the Securities Act.    ☐

 

 

The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.

 

 

 

Explanatory Note

GE HealthCare Technologies Inc. (“GE HealthCare” or the “Company”) is filing this Amendment No. 1 (the “Amendment”) to its Registration Statement on Form S-1 (File No. 333-268797) as an exhibits only filing to file Exhibits 5.1, 23.1, 23.2, 23.3, and 23.4. Since the filing of the Registration Statement on Form S-1 on December 14, 2022, GE HealthCare, formerly known as GE Healthcare Holding LLC, has converted into a corporation and has been re-named GE HealthCare Technologies Inc. This Amendment consists only of the facing page of the Registration Statement, this explanatory note, Part II of the Registration Statement, the signature pages to the Registration Statement, and the filed exhibits. Other than the aforementioned changes, the prospectus has not changed and has been omitted.

PART II

INFORMATION NOT REQUIRED IN PROSPECTUS

Item 13. Other Expenses of Issuance and Distribution.

The following table sets forth the costs and expenses payable by the registrant in connection with the issuance of the securities being registered. All amounts are estimates except the Securities and Exchange Commission registration fee.

 

Securities and Exchange Commission registration fee

    $ 2,635.28  

Legal fees and expenses

      50,000.00  

Accounting fees and expenses

      300,000.00  

Printing expenses

      50,000.00  

Total

    $ 402,635.28  

Item 14. Indemnification of Directors and Officers.

Delaware law authorizes corporations to limit or eliminate the personal liability of directors and officers to corporations and their stockholders for monetary damages for breaches of directors’ and officers’ fiduciary duties as directors or officers, as applicable, and our certificate of incorporation includes such an exculpation provision. The Company’s bylaws include provisions that indemnify, to the fullest extent allowable under the Delaware General Corporation Law (“DGCL”), the personal liability of directors or officers for monetary damages for actions taken as a director or officer of the Company, or for serving at our request as a director, officer, employee, or agent at another corporation or enterprise, as the case may be. The Company’s bylaws also provide that the Company must indemnify and advance expenses to the Company’s directors, officers, and employees, subject to the Company’s receipt of an undertaking from the indemnified party as may be required under the DGCL.

The limitation of liability and indemnification provisions that are included in the Company’s certificate of incorporation and bylaws, respectively, may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duty. These provisions may also have the effect of reducing the likelihood of derivative litigation against the Company’s directors and officers, even though such an action, if successful, might otherwise benefit the Company and its stockholders. However, these provisions will not limit or eliminate the Company’s rights, or those of any stockholder, to seek non-monetary relief such as an injunction or rescission in the event of a breach of a director’s duty of care. The provisions will not alter the liability of directors under the federal securities laws. In addition, your investment may be adversely affected to the extent that, in a class action or direct suit, the Company pays the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions. There is currently no pending material litigation or proceeding against any of the Company’s directors, officers, or employees for which indemnification is sought.

Reference is made to Item 17 for our undertakings with respect to indemnification for liabilities arising under the Securities Act.

The Company currently maintains insurance policies which, within the limits and subject to the terms and conditions thereof, covers certain expenses and liabilities that may be incurred by directors and officers in connection with proceedings that may be brought against them as a result of an act or omission committed or suffered while acting as a director or officer of the Company.

The Company will enter into an indemnification agreement with each of its directors that provides, in general, that the Company will indemnify them to the fullest extent permitted by law in connection with their service to the Company or on its behalf.

 

II-1

Item 15.

Recent Sales of Unregistered Securities.

On May 16, 2022, GE HealthCare issued 100 shares representing the limited liability interests in GE Healthcare Holding LLC, par value $0.01 per share, to GE for an aggregate consideration of $1.00. On December 29, 2022, after giving effect to GE HealthCare’s conversion from a limited liability company to a corporation, 453,869,824 shares of common stock, par value $0.01 per share, of GE HealthCare were held by GE. The shares of common stock described above were issued in reliance on the exemption contained in to Section 4(a)(2) of the Securities Act on the basis that the transaction did not involve a public offering. No underwriters were involved in the transaction.

 

Item 16.

Exhibits, Financial Statements and Financial Statement Schedules.

(a) Exhibits

 

    

Exhibit Description

    2.1    Separation and Distribution Agreement, dated as of November 7, 2022, by and between General Electric Company and the registrant (incorporated by reference to Exhibit 2.1 of GE Healthcare Holding LLC’s Registration Statement on Form 10 filed with the SEC on December 2, 2022, File No. 001-41528).†
    3.1    Certificate of Incorporation of the registrant (incorporated by reference to Exhibit 3.1 of GE HealthCare Technologies Inc.’s Current Report on Form 8-K filed with the SEC on December 29, 2022).
    3.2    Bylaws of the registrant (incorporated by reference to Exhibit 3.2 of GE HealthCare Technologies Inc.’s Current Report on Form 8-K filed with the SEC on December 29, 2022).
    4.1    Base Indenture, dated as of November  22, 2022, among GE Healthcare Holding LLC and The Bank of New York Mellon, as trustee (incorporated by reference to Exhibit 4.1 of GE Healthcare Holding LLC’s Registration Statement on Form 10 filed with the SEC on December 2, 2022, File No. 001-41528).
    4.2    First Supplemental Indenture, dated as of November  22, 2022, between GE Healthcare Holding LLC and The Bank of New York Mellon, as trustee (incorporated by reference to Exhibit 4.2 of GE Healthcare Holding LLC’s Registration Statement on Form 10 filed with the SEC on December 2, 2022, File No. 001-41528).
    4.3    Registration Rights Agreement, dated as of November  22, 2022, among GE Healthcare Holding LLC, BofA Securities, Inc., and Morgan Stanley  & Co. LLC (incorporated by reference to Exhibit 4.3 of General Electric Company’s Current Report on Form 8-K filed with the SEC on November 23, 2022).
    5.1    Opinion of Paul, Weiss, Rifkind, Wharton & Garrison LLP.*
  10.1    Form of Transition Services Agreement, by and between General Electric Company and the registrant (incorporated by reference to Exhibit 10.1 of GE Healthcare Holding LLC’s Registration Statement on Form 10 filed with the SEC on December 2, 2022, File No. 001-41528).
  10.2    Form of Tax Matters Agreement, by and between General Electric Company and the registrant (incorporated by reference to Exhibit 10.2 of GE Healthcare Holding LLC’s Registration Statement on Form 10 filed with the SEC on December 2, 2022, File No. 001-41528).
  10.3    Form of Employee Matters Agreement, by and between General Electric Company and the registrant (incorporated by reference to Exhibit 10.3 of GE Healthcare Holding LLC’s Registration Statement on Form 10 filed with the SEC on December 2, 2022, File No. 001-41528).
  10.4    Form of Trademark License Agreement, by and between General Electric Company and a subsidiary of the registrant (incorporated by reference to Exhibit 10.4 of GE Healthcare Holding LLC’s Registration Statement on Form 10 filed with the SEC on December 2, 2022, File No. 001-41528).†

 

II-2

    

Exhibit Description

  10.5    Form of Real Estate Matters Agreement, by and between General Electric Company and the registrant (incorporated by reference to Exhibit 10.5 of GE Healthcare Holding LLC’s Registration Statement on Form 10 filed with the SEC on December 2, 2022, File No. 001-41528).
  10.6    Form of Stockholder and Registration Rights Agreement, by and between General Electric Company and the registrant (incorporated by reference to Exhibit 10.6 of GE Healthcare Holding LLC’s Registration Statement on Form 10 filed with the SEC on December 2, 2022, File No. 001-41528).†
  10.7    Form of Indemnification Agreement (incorporated by reference to Exhibit 10.7 of GE Healthcare Holding LLC’s Registration Statement on Form 10 filed with the SEC on December 2, 2022, File No. 001-41528).
  10.8    Term Loan Agreement, dated as of November 4, 2022, by and among GE Healthcare Holding LLC, as the borrower, the lenders from time to time party thereto and Citibank, N.A., as administrative agent (incorporated by reference to Exhibit 10.8 of GE Healthcare Holding LLC’s Registration Statement on Form 10 filed with the SEC on December 2, 2022, File No. 001-41528).
  10.9    364-Day Revolving Credit Agreement, dated as of November 4, 2022, by and among GE Healthcare Holding LLC, as the borrower, the lenders from time to time party thereto and Citibank, N.A., as administrative agent (incorporated by reference to Exhibit 10.9 of GE Healthcare Holding LLC’s Registration Statement on Form 10 filed with the SEC on December 2, 2022, File No. 001-41528).
  10.10    Credit Agreement, dated as of November 4, 2022, by and among GE Healthcare Holding LLC, as the borrower, the lenders from time to time party thereto and Citibank, N.A., as administrative agent (incorporated by reference to Exhibit 10.10 of GE Healthcare Holding LLC’s Registration Statement on Form 10 filed with the SEC on December 2, 2022, File No. 001-41528).
  10.11    GE HealthCare 2023 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.11 of GE Healthcare Holding LLC’s Registration Statement on Form S-1 as filed with the SEC on December 14, 2022, File No. 333-268797).
  10.12    GE HealthCare Mirror 2022 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.12 of GE Healthcare Holding LLC’s Registration Statement on Form S-1 as filed with the SEC on December 14, 2022, File No. 333-268797).
  10.13    GE HealthCare Mirror 2007 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.13 of GE Healthcare Holding LLC’s Registration Statement on Form S-1 as filed with the SEC on December 14, 2022, File No. 333-268797).
  10.14    GE HealthCare Mirror 1990 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.14 of GE Healthcare Holding LLC’s Registration Statement on Form S-1 as filed with the SEC on December 14, 2022, File No. 333-268797).
  10.15    Offer Letter with Peter J. Arduini, dated June  15, 2021 (incorporated by reference to Exhibit 10.15 of GE Healthcare Holding LLC’s Registration Statement on Form 10 filed with the SEC on December 2, 2022, File No. 001-41528).
  10.16    Amended Offer Letter with Peter J. Arduini, dated November  16, 2022 (incorporated by reference to Exhibit 10.16 of GE Healthcare Holding LLC’s Registration Statement on Form 10 filed with the SEC on December 2, 2022, File No. 001-41528).
  10.17    Settlement Agreement with Kieran Murphy, dated December  21, 2021 (incorporated by reference to Exhibit 10.17 of GE Healthcare Holding LLC’s Registration Statement on Form 10 filed with the SEC on December 2, 2022, File No. 001-41528).
  10.18    Performance Share Grant Agreement for H. Lawrence Culp, Jr., dated August  18, 2020 (incorporated by reference to Exhibit 10.18 of GE Healthcare Holding LLC’s Registration Statement on Form 10 filed with the SEC on December 2, 2022, File No. 001-41528).
  10.19    Notice of Adjustment to the Performance Share Grant Agreement for H. Lawrence Culp, Jr., effective July  30, 2021 (incorporated by reference to Exhibit 10.19 of GE Healthcare Holding LLC’s Registration Statement on Form 10 filed with the SEC on December 2, 2022, File No. 001-41528).
  10.20    Performance Stock Unit Grant Agreement for Peter J. Arduini, dated February  23, 2022 (incorporated by reference to Exhibit 10.20 of GE Healthcare Holding LLC’s Registration Statement on Form 10 filed with the SEC on December 2, 2022, File No. 001-41528).
  10.21    GE HealthCare Annual Executive Incentive Plan (incorporated by reference to Exhibit 10.21 of GE Healthcare Holding LLC’s Registration Statement on Form 10 filed with the SEC on December 2, 2022, File No. 001-41528).

 

II-3

    

Exhibit Description

  10.22    GE HealthCare Restoration Plan (incorporated by reference to Exhibit 10.22 of GE Healthcare Holding LLC’s Registration Statement on Form 10 filed with the SEC on December 2, 2022, File No. 001-41528).
  10.23    GE HealthCare U.S. Executive Severance Plan (incorporated by reference to Exhibit 10.23 of GE Healthcare Holding LLC’s Registration Statement on Form 10 filed with the SEC on December 2, 2022, File No. 001-41528).
  16.1    Letter of KPMG, dated February  12, 2021 (incorporated by reference to Exhibit 16.1 of General Electric Company’s Current Report on Form 8-K filed with the SEC on February 12, 2021).
  21.1    Subsidiaries of the registrant (incorporated by reference to Exhibit 21.1 of GE Healthcare Holding LLC’s Registration Statement on Form 10 filed with the SEC on December 2, 2022, File No. 001-41528).
  23.1    Consent of Deloitte & Touche LLP.*
  23.2    Consent of Deloitte & Touche LLP.*
  23.3    Consent of KPMG LLP.*
  23.4    Consent of Paul, Weiss, Rifkind, Wharton & Garrison LLP (included in Exhibit 5.1).*
  99.1    Consent of H. Lawrence Culp, Jr. as Director Nominee (incorporated by reference to Exhibit 99.1 of GE Healthcare Holding LLC’s Registration Statement on Form S-1 as filed with the SEC on December 14, 2022, File No. 333-268797).
  99.2    Consent of Peter J. Arduini as Director Nominee (incorporated by reference to Exhibit 99.2 of GE Healthcare Holding LLC’s Registration Statement on Form S-1 as filed with the SEC on December 14, 2022, File No. 333-268797).
  99.3    Consent of Rodney F. Hochman as Director Nominee (incorporated by reference to Exhibit 99.3 of GE Healthcare Holding LLC’s Registration Statement on Form S-1 as filed with the SEC on December 14, 2022, File No. 333-268797).
  99.4    Consent of Lloyd W. Howell, Jr. as Director Nominee (incorporated by reference to Exhibit 99.4 of GE Healthcare Holding LLC’s Registration Statement on Form S-1 as filed with the SEC on December 14, 2022, File No. 333-268797).
  99.5    Consent of Anne T. Madden as Director Nominee (incorporated by reference to Exhibit 99.5 of GE Healthcare Holding LLC’s Registration Statement on Form S-1 as filed with the SEC on December 14, 2022, File No. 333-268797).
  99.6    Consent of Tomislav Mihaljevic as Director Nominee (incorporated by reference to Exhibit 99.6 of GE Healthcare Holding LLC’s Registration Statement on Form S-1 as filed with the SEC on December 14, 2022, File No. 333-268797).
  99.7    Consent of Risa Lavizzo-Mourey as Director Nominee (incorporated by reference to Exhibit 99.7 of GE Healthcare Holding LLC’s Registration Statement on Form S-1 as filed with the SEC on December 14, 2022, File No. 333-268797).
  99.8    Consent William J. Stromberg as Director Nominee (incorporated by reference to Exhibit 99.8 of GE Healthcare Holding LLC’s Registration Statement on Form S-1 as filed with the SEC on December 14, 2022, File No. 333-268797).
  99.9    Consent of Phoebe L. Yang as Director Nominee (incorporated by reference to Exhibit 99.9 of GE Healthcare Holding LLC’s Registration Statement on Form S-1 as filed with the SEC on December 14, 2022, File No. 333-268797).
107    Filing Fee Table (incorporated by reference to Exhibit 107 of GE HealthCare Holding LLC’s Registration Statement on Form S-1 as filed with the SEC on December 14, 2022, File No. 333-268797).

 

 

*

Filed herewith

†

Certain portions of this exhibit have been redacted pursuant to Item 601(b)(2)(ii) and Item 601(b)(10)(iv) of Regulation S-K, as applicable. The Company agrees to furnish supplementally an unredacted copy of the exhibit to the Securities and Exchange Commission upon its request.

(b)    Financial Statement Schedules

See the Index to Combined Financial Statements included on page F-1 for a list of the financial statements included in this registration statement.

 

Item 17.

Undertakings.

The undersigned registrant hereby undertakes:

 

  (1)

To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

 

  (i)

To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

 

II-4

  (ii)

To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of a prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement;

 

  (iii)

To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.

 

  (2)

That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

  (3)

To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

 

  (4)

That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities:

The undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:

 

  (i)

Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;

 

  (ii)

Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;

 

  (iii)

The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and

 

  (iv)

Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.

Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

 

II-5

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Chicago, state of Illinois, on December 29, 2022.

 

GE HealthCare Technologies Inc.
By:   /s/ Robert M. Giglietti
  Name: Robert M. Giglietti
  Title: Senior Vice President

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities indicated and on December 29, 2022.

 

Signature

   

Title

  

Date

*    President and Chief Executive Officer
(Principal Executive Officer)		   December 29, 2022
Peter J. Arduini
*    Chief Financial Officer (Principal Financial Officer)   December 29, 2022
Helmut Zodl
*    Controller and Chief Accounting Officer
(Principal Accounting Officer)		   December 29, 2022
George A. Newcomb
*    Director   December 29, 2022
Robert M. Giglietti
*    Director
   December 29, 2022
Catherine Lesjak
 

 

    Director  

 

Michael Holston

 

*By:   /s/ Jenny L. Lauth
  Jenny L. Lauth
  Attorney-in-Fact

 

II-6

EX-5.1

Exhibit 5.1

Paul, Weiss, Rifkind, Wharton & Garrison LLP

1285 Avenue of the Americas

New York, New York 10019-6064

212-373-3000

212-757-3990

December 29, 2022

GE HealthCare Technologies Inc.

500 W. Monroe Street

Chicago, IL 60661

Re: GE HealthCare Technologies Inc. Mirror 2022 Long-Term Incentive Plan

GE HealthCare Technologies Inc. Mirror 2007 Long-Term Incentive Plan

GE HealthCare Technologies Inc. Mirror 1990 Long-Term Incentive Plan

Registration Statement on Form S-1

(Registration No. 333-268797)

Ladies and Gentlemen:

We have acted as special counsel to GE HealthCare Technologies Inc., a Delaware corporation (the “Company”), in connection with the Registration Statement on Form S-1 (the “Registration Statement”) of the Company, filed with the Securities and Exchange Commission pursuant to the Securities Act of 1933, as amended (the “Act”), and the rules and regulations thereunder (the “Rules”). You have asked us to furnish our opinion as to the legality of the securities being registered under the Registration Statement. The Registration Statement relates to the registration under the Act of 1,906,984 shares (the “Shares”) of the Company’s common stock, par value $0.01 per share, issuable in respect of awards to be granted under the GE HealthCare Technologies Inc. Mirror 2022 Long-Term Incentive Plan, the GE HealthCare Technologies Inc. Mirror 2007 Long-Term Incentive Plan and the GE HealthCare Technologies Inc. Mirror 1990 Long-Term Incentive Plan (collectively, the “Plans”). The Company, which was a limited liability company named GE Healthcare Holding LLC, converted to a corporation and was renamed GE HealthCare Technologies Inc. on December 29, 2022 (the “Conversion”).

In connection with the furnishing of this opinion, we have examined originals, or copies certified or otherwise identified to our satisfaction, of the following documents (collectively, the “Documents”):

1. the Registration Statement; and

2. the Plans, included as Exhibits 10.12, 10.13 and 10.14 to the Registration Statement, and the forms of award agreements (collectively, the “Agreements”) relating to awards to be granted under the Plans.

In addition, we have examined (i) such limited liability company records of GE Healthcare Holding LLC that we have considered appropriate, including a copy of the certificate of formation and limited liability company agreement of GE Healthcare Holding LLC, certified by the Company as in effect immediately prior to the Conversion, copies of resolutions of the board of managers of GE Healthcare Holding LLC relating to the issuance of the Shares, certified by the Company, (ii) such corporate records of the Company that we have considered appropriate, including a copy of the certificate of conversion effectuating the Conversion, the certificate of incorporation and the bylaws of the Company, certified by the Company as in effect on the date of this letter and (iii) such other certificates, agreements and documents that we deemed relevant and necessary as a basis for the opinion expressed below. We have also relied upon the factual matters contained in the representations and warranties of the Company made in the Documents and upon certificates of public officials and the officers of the Company.

In our examination of the documents referred to above, we have assumed, without independent investigation, the genuineness of all signatures, the legal capacity of all individuals who have executed any of the documents reviewed by us, the authenticity of all documents submitted to us as originals, the conformity to the originals of all documents submitted to us as certified, photostatic, reproduced or conformed copies of valid existing agreements or other documents, the authenticity of all the latter documents and that the statements regarding matters of fact in the certificates, records, agreements, instruments and documents that we have examined are accurate and complete.

Based upon the above, and subject to the stated assumptions, exceptions and qualifications, we are of the opinion that the Shares have been duly authorized by all necessary corporate action on the part of the Company and, when issued and delivered in accordance with the terms of each applicable Plan and any applicable Agreement under such Plans, the Shares will be validly issued, fully paid and non-assessable.

The opinion expressed above is limited to the General Corporation Law of the State of Delaware and the Delaware Limited Liability Company Act. Our opinion is rendered only with respect to the laws, and the rules, regulations and orders under those laws, that are currently in effect.

We hereby consent to use of this opinion as an exhibit to the Registration Statement and to the use of our name under the heading “Certain Legal Matters” contained in the prospectus included in the Registration Statement. In giving this consent, we do not thereby admit that we come within the category of persons whose consent is required by the Act or the Rules.

Very truly yours,

/s/ PAUL, WEISS, RIFKIND, WHARTON & GARRISON LLP

PAUL, WEISS, RIFKIND, WHARTON & GARRISON LLP

EX-23.1

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the use in this Registration Statement No. 333-268797 on Form S-1 of our report dated July 29, 2022, relating to the financial statement of GE Healthcare Holding LLC. We also consent to the reference to us under the heading “Experts” in such Registration Statement.

/s/ Deloitte & Touche LLP

Chicago, Illinois

December 29, 2022

EX-23.2

Exhibit 23.2

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the use in this Registration Statement No. 333-268797 on Form S-1 of our report dated July 29, 2022, relating to the financial statements of GE HealthCare, a business of General Electric Company. We also consent to the reference to us under the heading “Experts” in such Registration Statement.

/s/ Deloitte & Touche LLP

Chicago, Illinois

December 29, 2022

EX-23.3

Exhibit 23.3

Consent of Independent Registered Public Accounting Firm

We consent to the use of our report dated July 29, 2022, with respect to the combined financial statements of GE HealthCare (a carve-out business of General Electric Company), included herein and to the reference to our firm under the heading “Experts” in the prospectus.

/s/ KPMG LLP

Chicago, Illinois

December 29, 2022